FDA approves Amgen’s BLINCYTO for expanded use in B-ALL treatment
Amgen (NASDAQ: AMGN) has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of BLINCYTO (blinatumomab) for the consolidation phase ... Read More
COURSE trial reveals promising results for TEZSPIRE in COPD patients with high eosinophil counts
In a significant development in chronic obstructive pulmonary disease (COPD) management, the Phase IIa COURSE trial, a proof-of-concept study led by AstraZeneca in partnership with ... Read More
Amgen seeks European approval for teprotumumab in thyroid eye disease
Amgen (NASDAQ: AMGN), a global biotechnology leader, has announced its plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ... Read More
Quantinuum closes $300m equity fundraise, valued at $5bn pre-money
Quantinuum, a global leader in integrated quantum computing, has announced the closing of a substantial $300 million equity fundraise. This financial milestone, achieved at a ... Read More
Glenmark Pharmaceuticals secures FDA approval for generic version of Otezla Tablets
Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S. FDA) for its Apremilast Tablets in 10 ... Read More
Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise value of around $28.3bn. The US biotechnology ... Read More
Amgen to acquire American biopharma company ChemoCentryx for $3.7bn
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth ... Read More
Liberty Mutual wraps up $515m acquisition of Malaysian insurer AmGeneral
Liberty Mutual Insurance has wrapped up the previously announced MYR 2.29 billion ($515 million) acquisition of AmGeneral Insurance Berhad, a Malaysian insurer, having secured regulatory ... Read More
Amgen, Generate Biomedicines sign $1.9bn worth research collaboration deal
Amgen has signed a research collaboration deal worth up to $1.9 billion with Cambridge-based Generate Biomedicines for the discovery and development of protein therapeutics for ... Read More
LUMAKRAS FDA approval : Amgen bags approval in KRAS G12C-mutated NSCLC
LUMAKRAS FDA approval : Amgen has bagged accelerated approval from the US Food and Drug Administration (FDA) for LUMAKRAS (sotorasib) for the treatment of a ... Read More